Artificial Intelligence (AI) In Genomics Market Summary

According to MRFR analysis, the AI in Genomics Market Size was valued at USD 14.22 Billion in 2024. The market is projected to grow from USD 16.76 Billion in 2025 to USD 86.85 Billion by 2035, registering a CAGR of 17.88% during the forecast 2025–2035. North America led the market with over 45.01% share, generating around USD 6.4 billion in revenue.

The AI in Genomics Market is expanding rapidly due to rising demand for precision medicine and increasing adoption of artificial intelligence in genomic research. Key trends include integration of machine learning in sequencing analysis, growing use in drug discovery, advancements in big data analytics, and expanding applications in disease prediction and personalized treatment strategies.

According to World Health Organization, genomics plays a critical role in understanding disease mechanisms and improving global health outcomes, supporting the growing use of AI in genomic data analysis.

Key Market Trends & Highlights

The AI in Genomics Market is poised for substantial growth driven by technological advancements and increasing demand for personalized healthcare solutions.

North America remains the largest market for AI in genomics, driven by robust investments in genomic research and technology.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by rapid advancements in genomic sequencing technologies.
The Drug Discovery segment continues to dominate the market, while the Personalized Medicine segment is experiencing the fastest growth due to rising consumer demand.
Advancements in machine learning algorithms and the growing adoption of genomic sequencing technologies are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size	14.22 (USD Billion)
2035 Market Size	86.85 (USD Billion)
CAGR (2025 - 2035)	17.88%

Major Players

Companies such as Illumina (US), Thermo Fisher Scientific (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), GRAIL (US), Freenome (US), Zymergen (US), BenevolentAI (GB), Genomatix (DE) are some of the major participants in the global market.

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Artificial Intelligence (AI) In Genomics Market Trends

The AI in Genomics Market is currently experiencing a transformative phase, driven by advancements in artificial intelligence technologies and their applications in genomic research. This market appears to be evolving rapidly, as organizations increasingly recognize the potential of AI to enhance data analysis, improve accuracy in genetic sequencing, and facilitate personalized medicine. The integration of machine learningalgorithms into genomic studies seems to streamline processes, enabling researchers to derive insights from vast datasets more efficiently.

Furthermore, collaborations between technology firms and healthcare institutions are likely to foster innovation, leading to novel solutions that address complex genetic disorders and enhance patient outcomes. In addition, the growing emphasis on precision medicine is propelling the demand for AI-driven genomic solutions. As healthcare systems shift towards more individualized treatment approaches, the role of genomics becomes increasingly pivotal.

This trend suggests that the AI in Genomics Market will continue to expand, with a focus on developing tools that can predict disease susceptibility and treatment responses based on genetic information. Overall, the landscape appears promising, with ongoing research and development efforts poised to unlock new possibilities in the realm of genomics and healthcare delivery.

Enhanced Data Analysis

The AI in Genomics Market is witnessing a trend towards improved data analysis capabilities. Advanced algorithms are being employed to process and interpret complex genomic data, allowing for more accurate insights and faster results. This trend indicates a shift towards more efficient research methodologies.

According to the World Health Organization, the rapid expansion of genomic and health data has significantly increased the need for advanced analytics, with over 120 countries adopting digital health strategies to strengthen data-driven healthcare systems.

Personalized Medicine Initiatives

There is a growing focus on personalized medicine within the AI in Genomics Market. As healthcare providers aim to tailor treatments based on individual genetic profiles, AI technologies are becoming essential in identifying the most effective therapies for patients. This trend highlights the importance of genomics in modern healthcare.

The World Health Organization emphasizes that precision medicine approaches leveraging genetic and molecular profiling are becoming central to modern healthcare, particularly in managing chronic and genetic diseases.

Collaborative Innovations

Collaborations between technology companies and healthcare organizations are becoming increasingly common in the AI in Genomics Market. These partnerships are fostering innovation and driving the development of new tools and solutions that address genetic disorders. This trend suggests a collective effort to enhance patient care through advanced genomic research.

The World Health Organization highlights the importance of multi-stakeholder collaboration in advancing digital health and genomic research, with governments, academia, and private sector entities working together to accelerate innovation.

Artificial Intelligence (AI) In Genomics Market Drivers

Rising Demand for Personalized Medicine

The AI in Genomics Market is significantly influenced by the rising demand for personalized medicine. As healthcare shifts towards tailored treatment plans, genomic data plays a crucial role in understanding individual patient profiles. This trend is evident in the increasing number of clinical trials focusing on genomics-based therapies. According to recent estimates, the personalized medicine market is expected to reach USD 2 trillion by 2030, with a substantial portion attributed to genomic innovations.

AI technologies facilitate the analysis of genomic data, enabling healthcare providers to develop customized treatment strategies. Consequently, the integration of AI in genomics is becoming essential for pharmaceutical companies aiming to enhance drug development processes and improve patient outcomes.

Increased Investment in Genomic Research

The AI in Genomics Market is benefiting from increased investment in genomic research. Governments and private entities are allocating substantial funds to explore the potential of genomics in various fields, including agriculture, healthcare, and biotechnology. For instance, funding for genomic research initiatives has seen a notable rise, with investments exceeding USD 10 billion in recent years.

This influx of capital is fostering innovation and collaboration among researchers, leading to the development of novel AI applications in genomics. As a result, the market is likely to expand as new technologies emerge, enabling more efficient data analysis and interpretation. The synergy between AI and genomics is expected to unlock new avenues for research and development, further solidifying the industry's growth trajectory.

Advancements in Machine Learning Algorithms

The AI in Genomics Market is experiencing a surge due to advancements in machine learning algorithms. These algorithms enhance the ability to analyze complex genomic data, leading to more accurate predictions and insights. For instance, the integration of deep learning techniques has shown promise in identifying genetic variants associated with diseases. As a result, the market is projected to grow at a compound annual growth rate of approximately 30% over the next five years.

This growth is driven by the increasing demand for precision medicine, which relies heavily on genomic data analysis. Furthermore, the ability of these algorithms to process vast datasets efficiently is likely to attract investments from both public and private sectors, further propelling the AI in Genomics Market.

Emergence of Collaborative Research Initiatives

The AI in Genomics Market is being shaped by the emergence of collaborative research initiatives. Partnerships between academic institutions, healthcare organizations, and technology companies are fostering innovation in genomics. These collaborations aim to leverage AI technologies to enhance data sharing and analysis capabilities. For example, initiatives that combine genomic data with clinical information are paving the way for breakthroughs in understanding complex diseases.

The collaborative approach is likely to accelerate the development of AI-driven solutions in genomics, as diverse expertise converges to tackle pressing challenges. This trend not only enhances the quality of research but also promotes the translation of findings into clinical applications, thereby driving the growth of the AI in Genomics Market.

Growing Adoption of Genomic Sequencing Technologies

The AI in Genomics Market is witnessing a growing adoption of genomic sequencing technologies. As sequencing costs continue to decline, more institutions are integrating these technologies into their research and clinical practices. The market for genomic sequencing is projected to reach USD 25 billion by 2026, driven by advancements in sequencing methods and the increasing availability of genomic data.

AI plays a pivotal role in analyzing the vast amounts of data generated by sequencing, enabling researchers to derive meaningful insights. This trend is likely to enhance the efficiency of genomic studies and accelerate the pace of discoveries in personalized medicine and disease prevention. The collaboration between AI and genomic sequencing is expected to redefine the landscape of genomics research.

Market Segment Insights

By Application: Drug Discovery (Largest) vs. Personalized Medicine (Fastest-Growing)

In the AI in Genomics market, the application segments are characterized by distinct roles across the industry. Drug Discovery currently holds the largest market share, driven by significant investments in AI technologies, which streamline the drug development process, thereby accelerating the time-to-market. Conversely, Personalized Medicine is gaining momentum as it leverages AI to tailor treatments based on genomic data, reflecting a growing consumer demand for customized healthcare solutions.

Drug Discovery (Dominant) vs. Personalized Medicine (Emerging)

Drug Discovery remains dominant in the AI in Genomics market due to its established methodologies and extensive funding focused on enhancing research and development. AI technologies are revolutionizing this space by predicting the efficacy and safety of drugs early in the process. On the other hand, Personalized Medicine is an emerging sector characterized by its innovative approach to tailoring health solutions based on individual genomic information. Fueled by advancements in AI, it significantly improves patient outcomes and aligns with the increasing shift toward tailored healthcare, making it an attractive investment and research area.

By Technology: Machine Learning (Largest) vs. Deep Learning (Fastest-Growing)

In the AI in Genomics Market, the distribution among the technology segments reveals that Machine Learning holds the largest share, attributed to its established foundation and broad application in genomic data analysis. It allows researchers to uncover complex patterns in large datasets quickly. Deep Learning, while a more recent innovation, is gaining traction due to its superior ability to handle unstructured data and generate insights that were previously unattainable. This segment is rapidly expanding as algorithms improve and computational power increases, making it a central player in next-gen genomics capabilities. The growth trends in these technologies are driven by advancements in computational capabilities and an increasing volume of genetic data. The integration of these technologies enables personalized medicine and advanced genome editing, enhancing the drug discovery process. As investments in genomics research continue to surge, especially from biotechnology firms, the demand for both Machine Learning and Deep Learning applications will only increase. Furthermore, the symbiotic relationship between these technologies and innovations in data collection techniques is poised to accelerate their adoption further.

Technology: Machine Learning (Dominant) vs. Deep Learning (Emerging)

Machine Learning has established itself as a dominant force in the market share, facilitating a plethora of applications from predictive modeling to genomic mapping. Its framework allows for efficient handling of large-scale genomic data, which correlates with existing biological knowledge to predict outcomes. Conversely, Deep Learning is recognized as an emerging technology, representing a shift towards advanced neural network architectures that are capable of identifying intricate patterns within genomic sequences. This growing segment is characterized by its capability to improve accuracy in gene expression analysis and disease prediction. As research in genome and phenotype correlations continues to evolve, both segments will play crucial roles in shaping treatment pathways and patient outcomes.

By Deployment Type: Cloud-Based (Largest) vs. On-Premises (Fastest-Growing)

In the AI in Genomics Market, the deployment type segment is prominently shaped by cloud-based solutions, which have solidified their position as the largest segment due to their scalability, accessibility, and cost-effectiveness. These solutions enable researchers and healthcare professionals to leverage vast computing resources without the upfront costs associated with physical hardware. On-premises deployment, while smaller in market share, is gaining traction among organizations with stringent data security and compliance requirements, as they prefer to maintain control over sensitive genomic data within their own infrastructure.

Deployment Type: Cloud-Based (Dominant) vs. On-Premises (Emerging)

Cloud-based deployment in the market share is characterized by its ability to provide flexible, scalable resources that cater to the dynamic computing needs of genomic research and analysis. This deployment method allows users to access powerful AI tools and large datasets from anywhere, facilitating collaboration among researchers across the globe. On the other hand, on-premises solutions are emerging as a viable choice for institutions that prioritize data security and privacy, as these setups offer greater control over data handling and regulatory compliance. These organizations are increasingly investing in on-premises infrastructure to accommodate specific use cases that require sensitive genomic data to remain within secure local environments, thus driving rapid growth in this segment.

By End User: Pharmaceutical Companies (Largest) vs. Healthcare Providers (Fastest-Growing)

In the AI in Genomics Market, Pharmaceutical Companies account for the largest share, leveraging AI technologies to improve drug discovery and development processes. They utilize genomics data to tailor treatments, resulting in more efficient and effective therapies. Meanwhile, Research Institutions and Biotechnology Firms play significant roles, but their shares are comparatively smaller, indicating a concentrated dominance by pharmaceutical players in this sector. Healthcare Providers, emerging as the fastest-growing segment, are increasingly adopting AI in genomics to enhance patient care, personalize treatments, and streamline operational efficiencies. The advancement in genomics and the integration of AI have also fostered collaborations between healthcare providers and genomic researchers, creating an ecosystem driven by innovation and patient-centric approaches.

Healthcare Providers (Dominant) vs. Biotechnology Firms (Emerging)

Healthcare Providers have established a dominant position in the market share as they increasingly adopt advanced genomic technologies to enhance patient outcomes. Their commitment to personalized medicine and efficient care delivery is driving innovative use cases for AI, such as predictive analytics and genomic data interpretation. Conversely, Biotechnology Firms represent an emerging force, leveraging AI to expedite drug discovery and development processes. While they may not hold the same market share as healthcare providers, their agile operations and focus on novel therapeutics position them as key players in the market, with potential for significant growth as collaboration between technology and biology continues to evolve.

By Solution Type: Software (Largest) vs. Services (Fastest-Growing)

In the AI in Genomics market, the solution type segment is predominantly led by software, which holds a significant share due to its essential role in data analysis and interpretation for genomic insights. Software solutions offer a range of functionalities, from machine learning algorithms to visualization tools, making them invaluable to genomics researchers and healthcare providers alike. Services represent the fastest-growing segment, as organizations seek expert consulting and implementation support to effectively integrate AI technologies into their genomic workflows.

Solution Type: Software (Dominant) vs. Services (Emerging)

Software solutions in the market share are recognized as the dominant force, providing essential tools for data management and analysis. Leading software offerings include platforms that leverage advanced algorithms to facilitate genetic data analysis, predictive modeling, and personalized medicine strategies. Conversely, the services segment is emerging rapidly due to the increasing demand for support services, including implementation, training, and technical assistance, as organizations navigate the complexities of AI integration. This growth is driven by the need for specialized knowledge and expertise to enhance the capabilities of existing genomic systems and maximize the benefits of AI technologies.

Get more detailed insights about Artificial Intelligence (AI) In Genomics Market

Request Free Sample

Regional Insights

North America leads in the AI in Genomics Market Size, accounting for over 45.01% of the global revenue in 2024, mainly driven by high investments in genomic research and advanced healthcare infrastructure. In contrast, Europe AI in Genomics Market was valued at USD 4.27 billion in 2024, making it the second-largest regional market with a 30% share, with innovations in personalized medicine leading to a rise in its market share.

The APAC region is emerging rapidly, buoyed by an increase in healthcare spending and technological advancements in genomics. South America and MEA, while currently smaller sub-regions in the AI in Genomics Market revenue, are witnessing an increased focus on genetic research and diagnostics, facilitating growth opportunities ahead.

Within these regions, sub-segments such as Drug Discovery, projected to be valued at 15.75 USD Billion by 2032, and Genomic Data Analysis, expected to reach 9.9 USD Billion by 2032, are set to be significant contributors to the overall market expansion. Personalized Medicine is another critical area, with a growth forecast to reach 10.5 USD Billion by 2032, reflecting the intensifying trend toward individualized healthcare solutions.

The continued evolution of diagnostic technologies and their applications in Agrigenomics, valued at 6.0 USD Billion by 2032, also represents an important segment within the AI in Genomics Market segmentation, revealing the comprehensive nature of this industry amidst various regional dynamics and emerging trends.

Artificial Intelligence (AI) In Genomics Market Regional Image

Key Players and Competitive Insights

The AI in Genomics Market is evolving rapidly, driven by advancements in artificial intelligence technologies and the increasing volume of genomic data. This market encompasses a variety of applications ranging from drug discovery, personalized medicine, genetic testing, and data analysis, resulting in a competitive landscape that features numerous players vying for technological superiority and market share.

Key factors influencing the dynamics of this market include innovation in machine learning algorithms, enhanced computational power, regulatory challenges, and the increasing awareness of genomics in healthcare.Companies in this field are exploring collaborative efforts, partnerships, and mergers and acquisitions to enhance their product offerings and expand their reach, resulting in a constant reshuffling of competitive positioning.

DnaNudge stands out in the AI in Genomics Market with its unique approach to integrating genomics and consumer health. The company's strength lies in its proprietary technology that enables real-time genetic testing and personalized dietary recommendations, allowing users to make informed lifestyle choices based on their genetic profiles. DnaNudge’s innovative platform leverages artificial intelligence to interpret complex genomic data, resulting in actionable insights that resonate with health-conscious consumers and healthcare professionals alike.

The company is well-positioned in the market due to its user-friendly applications and the rising trend of personalized medicine. DnaNudge's focus on consumer engagement and empowerment through genetic insights strengthens its competitive advantage, making it a notable player in the genomic landscape.BioSymetrics operates within the AI in Genomics Market, specializing in AI-driven solutions for understanding complex biological data. This company focuses on combining clinical, genomic, and biometric data to develop predictive models that can enhance drug discovery processes and facilitate targeted therapeutic strategies.

BioSymetrics has established a unique data architecture that allows for the integration and analysis of multi-modal data, which is essential in the personalized medicine arena. The strength of BioSymetrics lies in its cutting-edge algorithms and analytical capabilities that streamline the translation of genomic data into clinical applications. The company’s commitment to innovation and a deep focus on machine learning techniques empower it to deliver valuable insights to researchers and healthcare providers, placing BioSymetrics as a competitive entity in the ever-growing AI genomics space.

Key Companies in the Artificial Intelligence (AI) In Genomics Market include

Industry Developments

Q2 2024: Illumina and NVIDIA Collaborate to Accelerate AI Genomics Analysis Illumina announced a partnership with NVIDIA to integrate NVIDIA's AI computing platform into Illumina's genomics analysis workflows, aiming to speed up and scale genomic data interpretation for research and clinical applications.
Q2 2024: Fabric Genomics Raises $30 Million in Series C Funding to Advance AI-Driven Genomic Interpretation Fabric Genomics secured $30 million in Series C funding to expand its AI-powered genomic interpretation platform, supporting clinical diagnostics and precision medicine initiatives.
Q2 2024: Tempus Announces Acquisition of AI Genomics Startup Pangea Biomed Tempus, a leader in AI-driven precision medicine, acquired Pangea Biomed, an AI genomics startup, to enhance its oncology and rare disease genomics capabilities.
Q3 2024: Oxford Nanopore Technologies and Microsoft Partner to Develop AI Genomics Tools Oxford Nanopore Technologies entered a strategic partnership with Microsoft to co-develop AI-powered tools for real-time genomic data analysis, targeting healthcare and research markets.
Q3 2024: Grail Launches New AI-Enabled Genomic Cancer Screening Test Grail announced the commercial launch of a new AI-enabled genomic test designed to detect multiple types of cancer from a single blood draw, leveraging advanced machine learning algorithms.
Q3 2024: SOPHiA GENETICS Expands AI Genomics Platform to Asia Through Partnership with BGI SOPHiA GENETICS formed a partnership with BGI to expand its AI-powered genomics analytics platform into Asian markets, aiming to accelerate adoption in clinical and research settings.
Q4 2024: Deep Genomics Raises $100 Million Series D to Advance AI Drug Discovery Platform Deep Genomics closed a $100 million Series D funding round to further develop its AI-driven platform for genomic drug discovery and expand its therapeutic pipeline.
Q4 2024: PathAI Receives FDA Clearance for AI Genomics Companion Diagnostic PathAI announced FDA clearance for its AI-powered genomics companion diagnostic, enabling more precise patient selection for targeted cancer therapies.
Q1 2025: Celsius Therapeutics Raises $75 Million Series B to Scale AI Genomics Platform Celsius Therapeutics raised $75 million in Series B funding to scale its AI-driven genomics platform focused on autoimmune disease and oncology research.
Q1 2025: DNAnexus Launches AI-Enhanced Genomics Data Platform for Biopharma DNAnexus launched a new AI-enhanced genomics data platform designed to support biopharmaceutical companies in large-scale genomic data analysis and drug development.
Q2 2025: 23andMe Appoints New Chief AI Officer to Lead Genomics Innovation 23andMe appointed a Chief AI Officer to spearhead the company's efforts in integrating artificial intelligence into its consumer genomics and health research initiatives.
Q2 2025: Helix Opens New AI Genomics Research Facility in San Diego Helix announced the opening of a new research facility in San Diego dedicated to advancing AI-powered genomics research and accelerating the development of precision medicine solutions.

Future Outlook

Artificial Intelligence (AI) In Genomics Market Future Outlook

The AI in Genomics Market size is projected to reach USD 86.85 Billion by 2035, growing at a CAGR of 17.88%, driven by advancements in data analytics, personalized medicine, and genomic research.

New opportunities lie in:

Development of AI-driven genomic data analysis platforms
Integration of AI in precision medicine workflows
Creation of AI-based predictive models for genetic disorders

By 2035, the AI in Genomics Market is expected to be a pivotal sector in healthcare innovation.

Market Segmentation

Ai Genomics Market End User Outlook

Pharmaceutical Companies
Biotechnology Firms
Research Institutions
Healthcare Providers

Ai Genomics Market Technology Outlook

Machine Learning
Deep Learning
Natural Language Processing
Computer Vision

Ai Genomics Market Application Outlook

Drug Discovery
Genomic Data Analysis
Personalized Medicine
Agrigenomics
Diagnostics

Ai Genomics Market Solution Type Outlook

Software
Services

Ai Genomics Market Deployment Type Outlook

Cloud-Based
On-Premises

Report Scope

MARKET SIZE 2024	14.22(USD Billion)
MARKET SIZE 2025	16.76(USD Billion)
MARKET SIZE 2035	86.85(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	17.88% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Illumina (US), Thermo Fisher Scientific (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), GRAIL (US), Freenome (US), Zymergen (US), BenevolentAI (GB), Genomatix (DE)
Segments Covered	Applications, Technology, Deployment Type, End Users, Solution Type, Regional - Forecast to 2035
Key Market Opportunities	Integration of advanced machine learning algorithms enhances genomic data analysis and personalized medicine.
Key Market Dynamics	Rising integration of artificial intelligence in genomics enhances precision medicine and accelerates drug discovery processes.
Countries Covered	North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of AI in Genomics by 2035?

The AI in Genomics market is projected to reach a valuation of 86.85 USD Billion by 2035.

What was the market valuation of AI in Genomics in 2024?

In 2024, the AI in Genomics market was valued at 14.22 USD Billion.

What is the expected CAGR for the AI in Genomics market from 2025 to 2035?

The expected CAGR for the AI in Genomics market during the forecast period 2025 - 2035 is 17.88%.

Which application segment is projected to have the highest valuation by 2035?

The Genomic Data Analysis segment is projected to reach 21.12 USD Billion by 2035.

What are the leading technologies driving the AI in Genomics market?

Machine Learning and Deep Learning are leading technologies, with projected valuations of 30.0 USD Billion and 25.0 USD Billion, respectively, by 2035.

How does the deployment type of AI in Genomics market segment compare?

Cloud-Based deployment is expected to dominate with a projected valuation of 48.0 USD Billion by 2035, compared to 38.85 USD Billion for On-Premises.

Which end-user segment is anticipated to grow the most by 2035?

Pharmaceutical Companies are anticipated to grow significantly, reaching a valuation of 30.0 USD Billion by 2035.

What is the projected growth for software solutions in the AI in Genomics market?

Software solutions are projected to reach 30.0 USD Billion by 2035, indicating robust growth.

Who are the key players in the AI in Genomics market?

Key players include Illumina, Thermo Fisher Scientific, Bristol-Myers Squibb, and Regeneron Pharmaceuticals.

What is the projected valuation for the Diagnostics application segment by 2035?

The Diagnostics application segment is projected to reach a valuation of 17.65 USD Billion by 2035.

Author

Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment